ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Evangeline R JacksonRyan J DuchatelDilana E StaudtMika L PerssonAbdul MannanSridevi YadavilliSarah ParackalShaye GameWai Chin ChongW Samantha Nilanthi JayasekaraMarion Le GrandPadraic S KearneyAlicia M DouglasIzac J FindlayZacary P GermonHolly P McEwenTyrone S BeitakiAdjanie PatabendigeDavid A Skerrett-ByrneBrett NixonNathan D SmithBryan W DayNeevika ManoharanSumanth NagabushanJordan R HansfordDinisha GovenderGeoffrey B McCowageRon FiresteinMeegan HowlettRaelene EndersbyNicholas G GottardoFrank AlvaroSebastian M WaszakMartin Rössel LarsenYolanda Colino-SanguinoFatima Valdes MoraAndria RakotomalalaSamuel MeignanEddy PasquierAnne Isabelle BertozziEsther HullemanDavid D EisenstatNicholas A VitanzaJavad NazarianCarl J KoschmannRomain MuellerJason E CainMatthew D DunPublished in: Cancer research (2023)
PI3K/Akt signaling promotes metabolic adaptation to ONC201-mediated disruption of mitochondrial energy homeostasis in diffuse intrinsic pontine glioma, highlighting the utility of a combination treatment strategy using ONC201 and the PI3K/Akt inhibitor paxalisib.